GAPDHS and stroke disorder: Only when we observe the delayed treatment effect (administrated 1 h or later after stroke onset) with our TAT-GAPDH2–2–1–1 peptide in the future experiments, we can confirm the delayed effect is indeed because of the modeling issue.